A Phase 3, Interventional, Randomized, Multicenter, Open-label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib

Protocol No
DECIPHERA-DCC-2618-03-002
Principal Investigator
John Charlson
Phase
III
Summary
In this study we want to learn more about the safety of a new drug for GIST, DCC-2618 and how well it works against cancer in patients who have received imatinib as compared to Sutent (sunitinib), a routine treatment for GIST. DCC-2618 is still experimental and is not approved by the U.S. Food and Drug Administration. We don't know if this study will help you. Your condition may get better but it could stay the same or even get worse. We hope the information from this study will help us develop a better treatment for GIST in the future.
Description
DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: